Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.

Immune checkpoint inhibitors have recently received the U.S. Food and Drug Administration and European Medical Agency approval as first and second-line treatment for non-small cell lung cancer (NSCLC) [1 –3].

Source: Seminars in Arthritis and Rheumatism - January 6, 2018 Category: Rheumatology Authors: Marco Filetti, Elisabetta Anselmi, Serena Macrini, Francesco Rizzo, Daniela Iacono, Raffaele Giusti, Paolo Marchetti Source Type: research